Patents by Inventor Anne-Laure Flamar

Anne-Laure Flamar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion proteins comprising antibody and HPV E6 and E7 antigens
    Patent number: 9102734
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: August 11, 2015
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon Oh
  • Anti-CD40 targeted fusion proteins
    Patent number: 8961991
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: February 24, 2015
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
  • VACCINES BASED ON TARGETING ANTIGEN TO DCIR EXPRESSED ON ANTIGEN-PRESENTING CELLS
    Publication number: 20140134168
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Application
    Filed: October 3, 2013
    Publication date: May 15, 2014
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Antigen Presenting Cell Targeted Anti-Viral Vaccines
    Publication number: 20140127198
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: August 26, 2013
    Publication date: May 8, 2014
    Applicant: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
  • Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
    Patent number: 8586052
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: November 19, 2013
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Fusion protein with HIV antigen
    Patent number: 8518410
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: August 27, 2013
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
  • Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
    Patent number: 8449888
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: May 28, 2013
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells
    Publication number: 20120237513
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Application
    Filed: April 24, 2012
    Publication date: September 20, 2012
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard Zurawski, Jacques Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells
    Publication number: 20120231023
    Abstract: The present invention includes compositions and methods for enhancing an immune response with an adjuvant composition comprising: an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of Toll-Like Receptor (TLR) agonist, more specifically a TLR7 ligand (TLR7L), and a pharmaceutically acceptable carrier, wherein the conjugate and agonist are each comprised in an amount such that, in combination with the other, are effective to produce the immune response in a human or animal subject in need of immunostimulation.
    Type: Application
    Filed: March 8, 2012
    Publication date: September 13, 2012
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Robert R. Kane
  • NOVEL VACCINE ADJUVANTS BASED ON TARGETING ADJUVANTS TO ANTIBODIES DIRECTLY TO ANTIGEN-PRESENTING CELLS
    Publication number: 20120039916
    Abstract: Compositions and methods for enhancing an immune response with an adjuvant composition comprising: an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of a TLR agonist; and a pharmaceutically acceptable carrier are disclosed herein. The conjugate and agonist are each comprised in an amount such that, in combination with the other, are effective to produce the immune response in a human or animal subject in need of immunostimulation.
    Type: Application
    Filed: August 12, 2011
    Publication date: February 16, 2012
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar
  • Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells
    Publication number: 20120004643
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Application
    Filed: September 16, 2011
    Publication date: January 5, 2012
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard Zurawski, Jacques Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
    Patent number: 8057798
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: November 15, 2011
    Assignee: Baylor Research Institute
    Inventors: Gerald Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Multivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody
    Publication number: 20100330115
    Abstract: The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates.
    Type: Application
    Filed: June 21, 2010
    Publication date: December 30, 2010
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard Zurawski, Anne-Laure Flamar, Eynav Klechevsky
  • ANTIGEN PRESENTING CELL TARGETED CANCER VACCINES
    Publication number: 20100322929
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: March 4, 2010
    Publication date: December 23, 2010
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes, Peter Klucar, Keiko Akagawa
  • ANTIGEN PRESENTING CELL TARGETED VACCINES
    Publication number: 20100297114
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: March 4, 2010
    Publication date: November 25, 2010
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
  • ANTIGEN PRESENTING CELL TARGETED ANTI-VIRAL VACCINES
    Publication number: 20100291082
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: March 4, 2010
    Publication date: November 18, 2010
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
  • Multivariable antigens complexed with targeting humanized monoclonal antibody
    Patent number: 7786267
    Abstract: The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: August 31, 2010
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Anne-Laure Flamar, Eynav Klechevsky
  • HIV VACCINE BASED ON TARGETING MAXIMIZED GAG AND NEF TO DENDRITIC CELLS
    Publication number: 20100135994
    Abstract: The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cyclin D1.
    Type: Application
    Filed: July 16, 2009
    Publication date: June 3, 2010
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Anne-Laure Flamar, Amanda Cobb, Holly Mead, Monica Montes